Biotech firms AbCellera, Silence Therapeutics, and InduPro secure substantial capital raises
AbCellera raised $200 million through a share offering after reporting positive Phase 2 trial results for a hot flashes treatment. Silence Therapeutics and InduPro also completed significant funding rounds. The capital will support continued drug development programs across the three companies.
Related stories
Khartis Therapeutics Secures $50M Series B for Thyroid Eye Disease Treatment · Drug development
Abcuro secures $66 million to advance Phase 3 trial in milder form of muscle disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “AbCellera, Silence and InduPro all raise significant funding.” Browse more stories.